Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model [Yahoo! Finance]
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: Yahoo! Finance
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female mice Treatment preserved hepatic autophagy and maintained normal liver cellular homeostasis Findings support continued development of HT-VA for metabolic dysfunction associated with obesity and MASLD NEW YORK March 10, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs, today announced new female-specific preclinical results from the second phase of its metabolic disease study evaluating glial cell-derived neurotrophic factor (GDNF) (PRNewsfoto/Hoth Therapeutics Inc.) The second phase of the study evaluated serum liver biochemistry and hepatic molecular pathways in female mice fed a western diet to model metabolic dysfunction associated with obesity and Metabolic Dysfunction-Associated Steatotic Liver Diseas
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD ModelPR Newswire
- Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology ProgramPR Newswire
- HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASESPR Newswire